Francesca Bobbio Pallavicini

Medicine & Life Sciences

1. Rheumatoid Arthritis 100%
2. Tumor Necrosis Factor Inhibitors 47%
3. Antirheumatic Agents 27%
4. Tumor Necrosis Factor-alpha 24%
5. Anti-Citrullinated Protein Antibodies 23%
6. Infliximab 22%
7. Rheumatoid Factor 21%
8. Synovitis 20%
9. Therapeutics 19%
10. Psoriatic Arthritis 18%
11. Safety 17%
12. Registries 13%
13. Thoracic Aortic Aneurysm 13%
14. Giant Cell Arteritis 13%
15. Arthritis 13%
16. Coronavirus 12%
17. Rheumatic Diseases 12%
18. Systemic Scleroderma 12%
19. Observational Studies 12%
20. Autoantibodies 12%
21. Etanercept 12%
22. Methotrexate 11%
23. Antibodies 11%
24. SS-A antibodies 10%
25. Infections 10%
26. Undifferentiated Connective Tissue Diseases 10%
27. Rheumatology 10%
28. Joints 9%
29. Adrenal Cortex Hormones 9%
30. Pharmaceutical Preparations 8%
31. Italy 8%
32. golimumab 7%
33. C-Reactive Protein 7%
34. B-Lymphocytes 7%
35. Immunoglobulin A 7%
36. Arteries 7%
37. SARS Virus 7%
38. Immunosuppressive Agents 7%
39. Polymyalgia Rheumatica 7%
40. Immunoglobulin G4-Related Disease 7%
41. Denosumab 7%
42. Blood Sedimentation 7%
43. Prospective Studies 7%
44. Hepatitis B Core Antigens 6%
45. Minor Salivary Glands 6%
46. Dimercaprol 6%
47. Hepatitis B Antibodies 6%
48. Adalimumab 6%
49. Immunoglobulin M 6%
50. Biopsy 6%